Press Releases

August 6, 2020
— Completed last patient visits in Phase 3 PFIC and Phase 2 NASH Trials   — —  Enrolled first biliary atresia patients in second odevixibat pivotal study — —  Completed two financing transactions to secure cash into beginning of 2022 — —  Management to host conference call and webcast today at
July 30, 2020
BOSTON , July 30, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma , Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper , President and Chief Executive Officer, will participate in a fireside chat presentation
July 30, 2020
—  Conference call and webcast to be held at 10:00 a.m. ET   —  BOSTON , July 30, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a conference call
May 26, 2020
BOSTON , May 26, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma , Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper , President and Chief Executive Officer, will present via webcast at the 2020 Jefferies